Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

Vatiquinone

Source date not recordedAnalyse record ↗

15-lipoxygenase inhibitor in continuing and newly registered Phase 3 Friedreich-ataxia studies following an FDA request for additional evidence.

Modality
oral small-molecule 15-lipoxygenase inhibitor
Availability (US)
Phase 3 extension Active, not recruiting; new Phase 3 PROVE-FA study registered as Not yet recruiting after a 2025 FDA Complete Response Letter
Biomarkers
modified Friedreich’s Ataxia Rating Scale; treatment-emergent adverse events; pharmacokinetics
Hallmark targeted
mitochondrial dysfunction, oxidative stress, lipid peroxidation, ferroptosis
Kind
investigational drug
Clinical trials
NCT05515536 — Phase 3, Active, not recruiting on October 30, 2025 update; NCT07681713 — Phase 3, Not yet recruiting on August 14, 2026 update